{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T02:02:23Z","timestamp":1784340143222,"version":"3.55.0"},"reference-count":101,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2016,12,16]],"date-time":"2016-12-16T00:00:00Z","timestamp":1481846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA184418"],"award-info":[{"award-number":["K08CA184418"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Major advances in genetic and epigenetic profiling of acute lymphoblastic leukaemia (\n                    <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>\n                    ) have enhanced the understanding of key biological subsets of\n                    <jats:italic>de novo<\/jats:italic>\n                    and relapsed\n                    <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>\n                    , which has led to improved risk stratification of patients. These achievements have further defined critical leukaemia\u2010associated pathways and somatic alterations that may be preferentially sensitive to treatment with kinase inhibitors, epigenetic therapy or other novel agents. Therapeutic success in childhood\n                    <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>\n                    currently relies upon refined risk stratification of patients based on (i) underlying biological and clinical characteristics, and (ii) depth of initial treatment response with appropriate modulation of chemotherapy intensity. This review describes the current mutational landscape of childhood\n                    <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>\n                    and discusses opportunities for substantial improvements in survival with implementation of molecularly targeted therapies.\n                  <\/jats:p>","DOI":"10.1111\/bjh.14474","type":"journal-article","created":{"date-parts":[[2016,12,17]],"date-time":"2016-12-17T11:17:22Z","timestamp":1481973442000},"page":"867-882","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics"],"prefix":"10.1111","volume":"176","author":[{"given":"Sarah K.","family":"Tasian","sequence":"first","affiliation":[{"name":"Division of Oncology and Center for Childhood Cancer Research Children's Hospital of Philadelphia Philadelphia PA USA"},{"name":"Department of Pediatrics Perelman School of Medicine at the University of Pennsylvania and Abramson Cancer Center Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Hunger","sequence":"additional","affiliation":[{"name":"Division of Oncology and Center for Childhood Cancer Research Children's Hospital of Philadelphia Philadelphia PA USA"},{"name":"Department of Pediatrics Perelman School of Medicine at the University of Pennsylvania and Abramson Cancer Center Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,12,16]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3230"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.1325"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09221.x"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61341-0"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2011.1.354"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70377-7"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-633685"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2498"},{"issue":"7","key":"e_1_2_9_10_1","article-title":"Addition of FLT3 inhibitor lestaurtinib to post\u2010induction chemotherapy does not improve outcomes in mll\u2010rearranged infant acute lymphoblastic leukemia (All): AALL0631, a Children's Oncology Group Study","volume":"63","author":"Brown P.","year":"2016","journal-title":"Pediatric Blood & Cancer (SIOP 2016 Scientific Programme+Index)"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-509463"},{"key":"e_1_2_9_12_1","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1182\/blood.V126.23.2622.2622","article-title":"Clonal evolution and lack of BCR\u2010ABL1 mutations in pediatric Ph+ ALL patients resistant\/refractory to imatinib treatment","volume":"126","author":"Cazzaniga V.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09039.x"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.277"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-532598"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1998"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70314-0"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1001064107"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.088674"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.318"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70339-5"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.565436"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-351403"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.169"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14143"},{"key":"e_1_2_9_26_1","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1182\/blood.V124.21.3703.3703","article-title":"Initial results from a phase 2 study of blinatumomab in pediatric patients with relapsed\/refractory B\u2010cell precursor acute lymphoblastic leukemia","volume":"124","author":"Gore L.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.3"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.317"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2532"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1400972"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.8018"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.12.013"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-531871"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-704973"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-596403"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"e_1_2_9_38_1","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1182\/blood.V124.21.3718.3718","article-title":"Dasatinib shows therapeutic potential in the murine xenograft model for TCF3 rearranged acute lymphoblastic leukemia","volume":"124","author":"Lenz K.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.124016"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13115"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3840"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11790"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.04.038"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.149"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7604"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.107"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-273532"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4469"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-415448"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-580480"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-580068"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.04.008"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2558"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-112920"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61203"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164266"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808253"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.469"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09727"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-671131"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053190"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.0698"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.80"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12882"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3301"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-595744"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.1636"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70082-3"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.80"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1900"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403088"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2011.1.238"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-208397"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6000"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2010.07.126"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-338707"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.2514"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.30"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-670166"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2754"},{"key":"e_1_2_9_82_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.10006","article-title":"Outcomes of dasatinib plus intensive chemotherapy or stem cell transplant (SCT) for Philadelphia chromosome\u2010positive acute lymphoblastic leukemia (Ph+ ALL) on Children's Oncology Group AALL0622","volume":"33","author":"Slayton W.B.","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.1.18"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620713498161"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29573"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3078"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-577270"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61269"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.542"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.130179"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70600-9"},{"key":"e_1_2_9_92_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1102160"},{"key":"e_1_2_9_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2012.01.007"},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25470"},{"issue":"21","key":"e_1_2_9_95_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V124.21.1.1","article-title":"T\u2010lymphoblastic leukemia (T\u2010ALL) shows excellent outcome, lack of significance of the early thymic precursor (ETP) immunophenotype, and validation of the prognostic value of end\u2010induction minimal residual disease (MRD) in Children's Oncology Group (COG) Study AALL0434","volume":"124","author":"Wood B.L.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-165027"},{"key":"e_1_2_9_97_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.7"},{"key":"e_1_2_9_98_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3535"},{"key":"e_1_2_9_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.924"},{"key":"e_1_2_9_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10725"},{"key":"e_1_2_9_101_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3177"},{"key":"e_1_2_9_102_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3691"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14474","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14474","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T16:45:06Z","timestamp":1696265106000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,16]]},"references-count":101,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1111\/bjh.14474"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14474","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727114940.793548068","asserted-by":"object"}]},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,16]]},"assertion":[{"value":"2016-12-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}